Treatment of Ewing's Sarcoma in Cutaneous or Subcutaneous Presentation
Clinical Scenario
Ewing's sarcoma arising in a cutaneous or subcutaneous location represents a distinct subset. Retrospective evidence indicates this presentation carries a better prognosis compared with other localised soft tissue Ewing sarcoma, which directly shapes treatment planning.
Key Consideration
Because of the more favourable prognosis, the number of treatment cycles is not standardised. It is determined on an individual basis through multidisciplinary discussion and shared decision-making with the patient.
Treatment Approach
Management is multimodal, combining systemic chemotherapy with local therapy — the choice and extent of each component is guided by multidisciplinary assessment. The complete structured regimen is available below.
Clinical Goals
- Complete histological tumour response on surgical specimen assessment
- Reduction in size of soft tissue mass on MRI
References
DOI: 10.1016/j.annonc.2021.08.1995
- There is retrospective evidence suggesting that cutaneous and subcutaneous ES have a better prognosis compared with other localised soft tissue ES.
- Given their favourable prognosis, the number of cycles in cutaneous and subcutaneous ES is to be discussed case by case, at a multidisciplinary level and with the patient [V, C].
- Treatment of patients with extraskeletal ES follows the same principles as for bone ES, thus incorporating ChT in all cases as well as RT in most cases [IV, B].
- Complete surgical excision, where feasible, is regarded as the best modality of local control, given the higher risk of LR when RT is used as the sole treatment [IV, A].
- Recent studies suggest that 100% response is most optimal to define a good tumour response in ES.
- Change in the size of the soft tissue mass is easily evaluated on MRI, a good predictor of tumour response.
View source ↗